Fact-checked by Grok 2 weeks ago

Compound muscle action potential

The compound muscle action potential (CMAP), also known as the M wave, is the summated electrical response recorded from a following supramaximal electrical stimulation of its innervating motor nerve, representing the near-synchronous of all muscle fibers belonging to the activated motor units. This response is captured noninvasively using surface electrodes placed over the muscle belly and , providing a composite measure of neuromuscular conduction and muscle excitability. In electrophysiological studies, the CMAP is elicited by delivering a short-duration (typically 0.1–0.2 ms) supramaximal stimulus to the , often via electrodes, to ensure activation of all axons without fatigue. Key parameters include (measured from to the negative , reflecting the number and size of motor units), (time from stimulus to onset, indicating conduction velocity), duration (full width of the ), and area under the curve, all of which can vary with factors such as , , placement, and muscle . The typically exhibits a biphasic —initial negative deflection followed by a positive deflection—but may become polyphasic in conditions involving reinnervation or partial . Clinically, CMAP analysis is a cornerstone of nerve conduction studies (NCS) in (EMG), used to differentiate between axonal and demyelinating neuropathies, assess like (), and monitor disorders such as . Reduced CMAP amplitude often signals motor axon loss or conduction block, while prolonged latency points to demyelination; in , serial CMAP measurements serve as a for disease progression, correlating with motor unit number estimates (MUNE) and aiding in preclinical-to-clinical translation in animal models. Historically, CMAP evaluation evolved from early 20th-century M-wave recordings, with standardized techniques emerging in the –1970s to enhance diagnostic reliability.

Overview

Definition

The compound muscle action potential (CMAP) is the summated electrical response recorded from a muscle following supramaximal stimulation of its motor , representing the near-synchronous of s across multiple muscle fibers within the innervated motor units. This response arises when the stimulus intensity is sufficient to excite all axons in the , ensuring maximal of motor units and producing a reproducible that reflects the collective of the muscle tissue. Historically, the CMAP was referred to as the "M-wave" in early literature, a term denoting the muscle response to stimulation in contrast to sensory responses; this dates back to studies in the mid-20th century, such as those by Hodes et al. in 1948, who described it as a "muscle ," with "M potential" used by Brown in 1984. The modern term "compound muscle " emerged around 1973, as documented by Daube and Lambert, likely drawing from the concept of compound action potentials in studies to emphasize its composite nature. Over time, "CMAP" has become the preferred terminology in for precision. The CMAP differs from a single muscle action potential, which is the isolated electrical event generated by one fiber's depolarization, whereas the CMAP aggregates these individual events into a macroscopic signal. It also contrasts with the compound action potential (CNAP), which records the summated activity directly from axons rather than the downstream muscle response. Conceptually, the CMAP is generated through the summation of individual potentials, where the total waveform results from the vectorial addition of surface-detected motor unit potentials, and its amplitude is proportional to the number of activated fibers assuming uniform conduction and synchronization. This can be expressed as the CMAP approximating the sum \sum_i \text{MFAP}_i, with \text{MFAP}_i denoting the contribution from the i-th muscle action potential, though spatial and temporal dispersion influence the final recorded form.

Physiological Basis

The compound muscle action potential (CMAP) arises from the synchronized electrical activity of multiple muscle fibers within a following stimulation. When an arrives at the presynaptic terminal of a at the , voltage-gated calcium channels open, allowing calcium influx that triggers the of synaptic vesicles containing (ACh). The released ACh diffuses across the synaptic cleft and binds to nicotinic acetylcholine receptors on the postsynaptic motor endplate, opening ligand-gated channels that permit sodium influx, thereby generating an that depolarizes the muscle fiber membrane from its of approximately -90 mV to around -45 mV. This local depolarization exceeds the , initiating a propagating along the muscle fiber in both directions from the endplate toward the tendon ends. The of the muscle relies on voltage-gated sodium channels embedded in the , which open rapidly in response to the endplate depolarization, allowing a massive influx of sodium ions that further depolarizes the membrane to +30 mV or more, creating the upstroke of the . These channels, primarily the Nav1.4 isoform in , inactivate shortly after opening, while voltage-gated channels activate to repolarize the membrane by efflux, restoring the and enabling refractory periods that ensure unidirectional . This ionic mechanism ensures the travels at speeds of 2–5 m/s along the muscle , contributing to the overall CMAP waveform. Muscle conduction velocities typically range from 3–5 m/s in human , as determined using specialized electromyographic techniques that measure along individual fibers. The CMAP represents the algebraic of action potentials from all synchronously activated s in the stimulated muscle, where each 's potential is the sum of individual muscle fiber action potentials it innervates. Temporal occurs as action potentials from fibers within a arrive at the recording with slight delays due to varying conduction times, leading to overlap and cancellation that shapes the biphasic or triphasic CMAP . Spatial integrates potentials from multiple s across the 's detection area (typically 15–20 mm in diameter), amplifying the signal while factors like fiber density influence the waveform's complexity. The shape of the CMAP is influenced by muscle fiber properties, particularly diameter, which correlates positively with conduction velocity; larger-diameter fibers (e.g., 50–80 μm in fast-twitch types) conduct action potentials faster than smaller ones (20–40 μm in slow-twitch types), reducing temporal and yielding sharper waveforms. Variations in fiber diameter and internodal distances further modulate , affecting CMAP and without altering the fundamental process.

Recording and Measurement

Stimulation Techniques

Stimulation techniques for eliciting compound muscle action potentials (CMAPs) primarily involve supramaximal electrical stimulation of motor s to ensure activation of all motor axons, thereby producing a maximal response from the innervated muscle fibers. This approach is essential because submaximal stimulation may fail to recruit all motor units, leading to an incomplete CMAP that underestimates function. Electrical stimulators deliver pulses via surface electrodes placed directly over the , with constant-current devices preferred over constant-voltage types for their ability to maintain consistent current delivery despite variations in skin impedance, enhancing reliability and safety. Stimulation sites are selected along the course of the motor nerve to target specific segments, typically including a distal site near the muscle innervation and a proximal site further along the nerve trunk. For the , the distal site is commonly at the , approximately 8 cm proximal to the recording on the , while the proximal site is at the to allow measurement of conduction across the segment. These locations are chosen to isolate motor nerve responses and assess segmental conduction, with the positioned directly over the nerve and the 2-3 cm proximal to minimize stimulus spread. Key parameters of the stimulus include , , and pulse shape, optimized to achieve supramaximal activation while minimizing patient discomfort. Stimulus is gradually increased to 20-50 mA (or up to 100 mA in constant-current mode) until the CMAP amplitude plateaus, typically 10-30% above the maximal response to confirm supramaximality. is set to 0.05-0.2 ms, with 0.1-0.2 ms commonly used to balance effective depolarization and reduced artifact. A square-wave pulse shape is standard, providing a sharp onset and offset for precise excitation without unnecessary prolongation. Safety considerations emphasize precise electrode placement to avoid direct muscle stimulation, which could contaminate the CMAP with a non-nerve-mediated response, and to isolate pure motor nerve conduction. Shorter pulse durations and constant-current delivery help minimize discomfort and prevent excessive voltage exposure, particularly in patients with high skin resistance or implants like pacemakers, where grounding and low-intensity starts are critical.

Recording Methods

The recording of compound muscle action potential (CMAP) typically employs surface s to capture the summed electrical activity from muscle fibers. The active electrode (G1) is positioned over the muscle belly or motor point to maximize signal detection, while the (G2) is placed over the or an electrically inactive site to minimize baseline noise. A (G0) is attached proximally on the limb, ideally between the and recording sites, to further reduce . Circular surface electrodes with diameters of 10–18 mm are preferred for their reproducibility and higher recordings. Following electrode placement, the CMAP signal is amplified and filtered using specialized electrodiagnostic . Differential amplifiers with high common-mode rejection ratios (>100 dB) and input impedances (>100 MΩ) are standard to enhance the signal while attenuating common-mode noise, such as from the which can contribute up to 70–83% of the potential in certain nerves. Bandpass filters, typically set between 2–10 Hz and 10 kHz, are applied to isolate the relevant frequency components of the CMAP waveform and suppress low-frequency drift or high-frequency artifacts. Notch filters at 60 Hz are generally avoided, as they can introduce phase distortions. Display settings on the electrodiagnostic machine are adjusted to optimize visualization of the CMAP. Sweep speeds of 2–5 ms per division allow clear assessment of onset and , while settings of 1–5 mV per division accommodate the typical range without clipping. For precise measurement, finer (200–500 µV per division) may be used initially to ensure the onset exceeds one grid division. Artifacts can compromise CMAP quality, necessitating targeted . Patient movement is minimized by standardizing limb positions (e.g., elbow flexed at 90°) and instructing relaxation, while skin is cleaned with to lower impedance below 5 kΩ. Sixty Hz power-line is mitigated through proper grounding, short shielded cables, and incandescent lighting to avoid fluorescent-induced noise. To verify a supramaximal response, intensity is incrementally increased by 15–30% beyond the point of maximum CMAP amplitude until no further change occurs, often confirmed by observing muscle twitch.

Parameters and Interpretation

Key Parameters

The compound muscle action potential (CMAP) waveform is characterized by several key electrophysiological parameters that provide insights into nerve and muscle function. These parameters—amplitude, latency, duration, and area under the curve—are derived from the recorded voltage-time trace following supramaximal nerve stimulation and are essential for quantitative analysis in nerve conduction studies. Amplitude is typically measured as the -to- voltage difference or from to the negative , expressed in millivolts (). This parameter reflects the summation of action potentials from the activated muscle fibers and thus indicates the number and size of conducting motor axons and responsive muscle fibers. Reduced amplitude may arise from axonal loss or impaired neuromuscular transmission, as fewer fibers contribute to the overall response. Latency, specifically the onset , is the time interval in milliseconds () from the stimulus artifact to the initial deflection of the CMAP waveform. It primarily represents the conduction time along the fastest motor fibers, including contributions from distal segments, delay (approximately 1 ), and initial muscle fiber depolarization. Distal , measured over a fixed short (e.g., 7-8 cm from the stimulation site to the recording ), can be related to proximal and conduction velocity using the : distal = proximal - ( difference / conduction velocity), highlighting its role in assessing segmental conduction efficiency. Duration measures the temporal span in ms from the onset of the CMAP to its return to (or the point of the last positive peak). This parameter is influenced by the degree of among the activated muscle fibers, with increased often resulting from temporal dispersion due to varying conduction velocities across fibers. In normal conditions, it typically ranges from 5-6 ms, reflecting the coordinated of motor units. The area under the curve, calculated as the integrated voltage-time product in mV·ms, quantifies the total electrical activity of the CMAP by encompassing the entire negative and positive phases relative to . Unlike , which can be distorted by changes, this measure provides a more robust assessment of axonal integrity and the overall contribution of motor units, as it accounts for both height and width of the response. It is particularly useful in evaluating conditions where fiber desynchronization might affect values.

Normal Values and Variability

The compound muscle action potential (CMAP) exhibits well-established reference ranges in healthy adults, derived from large normative datasets adhering to standardized electrodiagnostic protocols. For the median nerve stimulating at the wrist to abductor pollicis brevis, the distal motor latency upper limit is typically 4.5 ms, CMAP amplitude lower limit is 4.1 mV, and motor conduction velocity lower limit is 49 m/s. Similar values for the ulnar nerve to abductor digiti minimi include a distal latency upper limit of 3.7 ms, amplitude lower limit of 7.9 mV, and conduction velocity lower limit of 52 m/s across the forearm. These ranges represent the 97th percentile for latencies and velocities (upper limits) and 3rd percentile for amplitudes (lower limits), based on studies of over 240 healthy subjects per nerve.
NerveStimulation Site to Recording MuscleDistal Motor Latency (Upper Limit, ms)CMAP Amplitude (Lower Limit, mV)Motor Conduction Velocity (Lower Limit, m/s)
Median to abductor pollicis brevis (8 cm)4.54.149
Ulnar to abductor digiti minimi (8 cm)3.77.952 ()
PeronealAnkle to extensor digitorum brevis (8 cm)6.51.338 (ankle-fibular head)
TibialAnkle to abductor hallucis (8 cm)6.14.439
Inter-individual variability in CMAP parameters arises from physiological factors such as , , and anthropometric measures. Age-related changes include a progressive decline in CMAP , with lower limits dropping from approximately 5.9 mV in individuals aged 19-39 years to 3.8 mV in those over 60 years for the , reflecting axonal loss and reduced size; conduction velocities also slow modestly with age, particularly in lower limbs. profoundly influences measurements, with limb cooling decreasing conduction velocity by approximately 2 m/s per °C below 34°C and prolonging distal latency by about 0.2 ms per °C, necessitating maintenance of above 32°C for upper limbs and 31°C for lower limbs during testing. correlates with slower conduction velocities in peroneal and tibial (e.g., 36 m/s lower for peroneal in taller adults >170 cm aged 40-79 years versus 43 m/s in shorter individuals), but has negligible impact on upper limb parameters. Technical variability in CMAP recordings is generally low, with showing of 5-11% on repeated testing under consistent conditions, enhancing reliability for serial evaluations. Population norms exhibit subtle differences by gender, with males often displaying slightly longer latencies (e.g., 4.6 ms upper limit in men aged 19-49 years versus 4.4 ms in women) but no major effects on ulnar or lower limb parameters; influences reference ranges, as seen in studies establishing higher thresholds in certain non-Caucasian cohorts compared to North American norms; limb dominance has minimal impact, with dominant-side velocities occasionally 1-2 m/s faster but not exceeding normative variability.

Clinical Applications

Diagnostic Uses

Compound muscle action potential (CMAP) measurements are essential in electrodiagnostic studies for distinguishing between axonal and demyelinating neuropathies. In axonal neuropathies, reduced CMAP reflects loss of motor axons, while conduction velocities and latencies remain relatively normal. In contrast, demyelinating neuropathies typically show prolonged distal latencies and slowed conduction velocities with preserved or only mildly reduced amplitudes until secondary axonal loss occurs. CMAP testing aids in diagnosing various polyneuropathies, such as , where mixed axonal and demyelinating features manifest as reduced CMAP and slowed conduction velocities in a symmetric, length-dependent pattern. For entrapment neuropathies like , focal prolongation of distal latency is a hallmark finding, often with normal CMAP in early stages before axonal involvement reduces it. In myopathies, CMAP are generally normal unless severe muscle fiber loss or distal atrophy is present, and reduced during maximal stimulation helps differentiate myopathic from neuropathic processes. In motor neuron diseases such as amyotrophic lateral sclerosis (ALS), CMAP amplitudes progressively decline with disease advancement, reflecting motor unit loss, and serial recordings serve as a biomarker for initial diagnosis and tracking progression. When evaluating mixed sensorimotor neuropathies, CMAP findings are interpreted alongside sensory nerve action potential (SNAP) measurements; reduced CMAP amplitudes indicate motor axon involvement, while absent or low SNAPs highlight sensory fiber pathology, enabling comprehensive assessment of both components.

Prognostic and Monitoring Value

In Guillain-Barré syndrome (GBS), low compound muscle action potential (CMAP) amplitude serves as a key prognostic indicator, with mean distal CMAP amplitudes below 20% of normal values strongly correlating with poor recovery and persistent disability at six months post-onset. Similarly, in traumatic nerve injuries such as , CMAP amplitudes greater than 10% of the contralateral side predict favorable outcomes, while amplitudes below this threshold indicate severe axonal loss and limited regeneration potential. Serial CMAP monitoring is valuable for assessing treatment efficacy in progressive neuromuscular conditions. In (SMA), particularly types 2 and 3, therapy stabilizes or increases CMAP amplitudes over time, with faster increments in amplitude associated with improved motor function in treated children after six months. In (DMD), serial CMAP amplitudes serve as an objective biomarker for disease severity and progression, sensitive to changes in number and size, aiding in evaluation of therapeutic interventions. For critical illness myopathy, repeated CMAP assessments track recovery from loss and axonal involvement, revealing amplitude improvements that align with weaning from and reduced . CMAP amplitude trajectories also correlate with functional outcomes in (). Declining CMAP amplitudes, especially in distal muscles, predict accelerated motor function loss as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R), providing a quantitative for progression beyond clinical scales alone. Diaphragmatic CMAP reductions further forecast respiratory decline, enhancing prognostic stratification in cohorts. Despite these applications, CMAP monitoring has limitations, including insensitivity to early subclinical changes, as amplitudes often remain normal until 30–50% loss occurs due to compensatory reinnervation. Additionally, it is less reliable for non-axonal pathologies, such as pure demyelination or myopathies without conduction block, where other electrodiagnostic measures like needle are needed for accurate tracking.

Abnormal Findings

Reduced Amplitude

Reduced amplitude of the compound muscle action potential (CMAP) primarily reflects a decrease in the number of muscle fibers activated by nerve stimulation, indicating loss of excitable tissue such as axons or muscle fibers. This reduction can arise from axonal degeneration, where fewer motor axons contribute to the response, as seen in various neuropathies. In myopathies, muscle fiber atrophy similarly diminishes the summated electrical activity, leading to lower CMAP amplitudes while preserving conduction velocities. Conduction block, a focal interruption of impulse propagation without axonal loss, also causes amplitude reduction when stimulation occurs proximal to the lesion site. Quantitatively, a CMAP amplitude less than 50% of the normal value or a side-to-side exceeding 50% often signifies significant , such as substantial axonal or muscle fiber loss. Temporal dispersion, where asynchronous fiber conduction broadens the , further contributes to reduction by cancellation of the summated potentials. In hereditary neuropathies like Charcot-Marie-Tooth disease, particularly axonal forms, CMAP amplitudes are severely reduced due to progressive axonal degeneration, often dropping below 1 mV in affected limbs. Post-denervation scenarios, such as after , exhibit markedly low CMAP amplitudes reflecting the extent of axonal dropout and muscle disuse . To differentiate conduction block from axonal loss or technical artifacts, stimulation at multiple sites along the nerve is essential: uniform low across distal and proximal sites points to axonal degeneration, whereas preserved distal with proximal reduction confirms conduction block. This approach helps rule out non-pathologic causes like suboptimal electrode placement.

Prolonged Latency and Duration

Prolonged latency of the compound muscle action potential (CMAP), specifically the distal motor latency (DML), reflects slowed conduction in the terminal nerve segments, typically resulting from demyelination that impairs and reduces . In demyelinating neuropathies, such as (CIDP), DML prolongation of ≥50% above the upper limit of normal (ULN) in two or more nerves serves as a definitive electrodiagnostic criterion for demyelination per the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) guidelines. This threshold helps distinguish pathological slowing from physiological variability, with examples including median nerve DML exceeding 6.3 ms (150% of ULN ≈4.2 ms) in affected patients. Increased CMAP duration arises from temporal , a phenomenon where heterogeneous conduction velocities among motor axons—due to focal or diffuse demyelination—cause desynchronized arrival of action potentials at the recording site, broadening the waveform. This is measured as a >30% increase in negative peak duration between distal and proximal stimulation sites in ≥2 nerves, or as distal CMAP duration exceeding 120% of ULN (from onset of the first negative peak to baseline return of the last) in ≥1 nerve, both of which are supportive criteria for demyelination in the updated European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) guidelines. In practice, CMAP duration may extend beyond 9.2 ms (per EAN/PNS 2021 criteria) in CIDP cases, highlighting the dispersion's role in waveform morphology. These abnormalities are prominent in immune-mediated demyelinating disorders like CIDP, where multifocal leads to consistent DML prolongation and across limbs, and (MMN), characterized by asymmetric weakness with focal conduction slowing, prolonged latencies, and temporal in nerves without sensory involvement. In MMN, distal latencies may exceed ULN by 50% or more in affected segments, often alongside conduction blocks. Prolonged DML directly impacts F-wave responses, as the F-wave latency incorporates twice the distal conduction time (orthodromic and antidromic), resulting in delayed minimal F-wave latencies (e.g., ≥120% of ULN) or absent F-waves in demyelinating neuropathies like CIDP and MMN; this correlation strengthens diagnostic evidence when combined with CMAP findings.

References

  1. [1]
    Revisiting the compound muscle action potential (CMAP) - PMC
    The quintessence of MUNE is the compound muscle action potential (CMAP) or “M wave” recorded from a muscle as a result of motor nerve stimulation. It is the ...
  2. [2]
    Action Potential Amplitude - an overview | ScienceDirect Topics
    Compound Muscle Action Potential (CMAP) is defined as the maximal electrical response recorded from a muscle, achieved through percutaneous stimulation of the ...
  3. [3]
    a study on compound muscle action potentials
    Compound muscle action potentials (CMAPs) are a simple neurophysiological test that measures the summation of muscle fiber depolarization in response to maximal ...
  4. [4]
  5. [5]
  6. [6]
  7. [7]
    [PDF] NERVE CONDUCTION STUDIES: PRACTICAL PHYSIOLOGY AND ...
    Since the active recording electrode overlies a muscle belly, the recorded response is a compound muscle action potential (CMAP), not a nerve action potential.Missing: CNAP | Show results with:CNAP
  8. [8]
    Neuromuscular response in man to repetitive nerve stimulation
    We studied change in the sizes of compound muscle action potentials (CMAPs) and compound nerve action potentials (CNAPs) in humans after a single electrical ...
  9. [9]
    Physiology, Neuromuscular Transmission - StatPearls - NCBI - NIH
    Mar 9, 2025 · The neuromuscular junction (NMJ) is responsible for the chemical transmission of electrical impulses from nerves to muscles (skeletal, smooth, or cardiac)
  10. [10]
    Voltage-gated sodium channels (Na V ): Introduction
    Voltage-gated sodium channels are responsible for action potential initiation and propagation in excitable cells, including nerve, muscle, and neuroendocrine ...
  11. [11]
    Skeletal Muscle Na+ Channel Disorders - PMC - NIH
    Voltage-gated sodium channels are essential in the generation and propagation of action potentials (APs) in excitable tissues such as muscle, heart, and nerve.
  12. [12]
    Distribution and function of voltage-gated sodium channels in the ...
    Voltage-gated sodium channels (VGSCs) are the basic ion channels for neuronal excitability, which are crucial for the resting potential and the generation ...
  13. [13]
    Electrophysiological characteristics of motor units and muscle fibers ...
    Apr 16, 2010 · The CMAP represents the summated action potentials of the motor units (MUs) activated by stimulation of the peripheral nerve. The MU is a single ...
  14. [14]
    Relation between muscle fiber conduction velocity and ... - PubMed
    We conclude that fiber diameter determines MFCV largely independent of the underlying neuromuscular disorders studied.
  15. [15]
    [PDF] CNCT Study Guide - AANEM
    This insures that the nerve will be fully stimulated and that a supramaximal stimulation and resultant maximal. SNAP or CMAP will be obtained. Theoretically ...
  16. [16]
  17. [17]
    [PDF] ANSA Inc NCS Guideline 2023
    INTRODUCTION. The following guidelines should be considered as minimum standards to perform routine common nerve conduction studies in clinical practice ...
  18. [18]
    Nerve Conduction Studies | PM&R KnowledgeNow - AAPM&R
    Jun 14, 2023 · Nerve Conduction Studies (NCSs) are a method to perform an extracellular recording of the intracellular process of neuron or muscle depolarization and action ...
  19. [19]
    Basic Nerve Conduction Studies | Musculoskeletal Key
    Mar 1, 2019 · For motor studies, the duration of the electrical pulse usually is set to 200 ms. Most normal nerves require a current in the range of 20 to 50 ...
  20. [20]
    Routine Clinical Electromyography - Thoracic Key
    Aug 12, 2016 · Surface recording electrodes are often made as small discs that are placed over the belly of the muscle or the nerve (Figure 2-2). The ...Missing: setup amplification
  21. [21]
    How to reduce noise interference in nerve conduction studies and ...
    The procedure begins with placing the electrodes to record neurophysiologic potentials. Cables or leads connect the electrodes to the amplifier. Much of noise ...
  22. [22]
  23. [23]
    Influence of age and height on nerve conduction - Wiley Online Library
    Aug 2, 2001 · Previous studies demonstrated age- and height-related slowing of nerve conduction velocity (NCV) and reduction in nerve response amplitude.
  24. [24]
    Effects of temperature on the excitability properties of human motor ...
    The conduction velocity increases by ~5% per degree C as the temperature of the nerve increases from 29 to 38°C (Johnson and Olsen, 1960; De Jesus et al., 1973; ...
  25. [25]
    Repeatability of nerve conduction measurements derived entirely by ...
    Nov 6, 2009 · CMAP and SNAP amplitude parameters have a higher CoV at 5-11%. Low CoV values between tests within a session (i.e., same electrode placement ...
  26. [26]
    Normative Data for Ulnar Nerve Conduction and the Influence of ...
    Mar 18, 2022 · The objective of the study was to generate normative values for motor and sensory ulnar nerve conduction studies (NCSs) in Nigerian population
  27. [27]
    Electrodiagnostic Evaluation of Peripheral Neuropathy - NCBI - NIH
    Jan 30, 2023 · Electrodiagnostic testing, which includes nerve conduction studies (NCS) and needle electromyography (EMG), can support the diagnosis of peripheral neuropathy.
  28. [28]
    Electrodiagnostic Evaluation of Myopathy - StatPearls - NCBI - NIH
    Oct 17, 2022 · Nerve conduction studies are usually normal in myopathies, except for severe distal weakness and muscle atrophy in distal myopathies when CMAP ...
  29. [29]
    Electrodiagnosis in Amyotrophic Lateral Sclerosis - PubMed Central
    Thus the electrodiagnostic evaluation is not only useful in diagnosis, but is also helpful in monitoring progression of the disease, response to interventions, ...Electrodiagnosis In... · Fasciculation Potentials · Other Needle Emg...
  30. [30]
    Motor conduction studies in guillain‐barré syndrome: Description ...
    In multivariate analysis of the motor conduction parameters, mean distal CMAP amplitude was the single best predictor of prognosis; other measures did not add ...
  31. [31]
    Prognostic values of electrodiagnostic studies in traumatic radial ...
    Jun 22, 2007 · Based on reports in the facial nerve literature that a CMAP amplitude of 10% or greater predicts a good prognosis, we set our CMAP amplitude ...
  32. [32]
    Study on the efficacy, safety, and biomarkers of nusinersen in type II ...
    Dec 3, 2023 · Patients with faster CMAP increase tend to have better motor function after treatment with nusinersen (12). Therefore, CMAP may be a biomarker ...<|control11|><|separator|>
  33. [33]
    Critical illness myopathy: Further evidence from muscle‐fiber ...
    Aug 30, 2007 · Serial studies help define the course of ... CMAP amplitudes, and EMG findings consistent with a myopathy or electrically inactive muscle.
  34. [34]
    Advancing disease monitoring of amyotrophic lateral sclerosis with ...
    CMAP scan-derived markers show promise in monitoring disease progression in ALS patients, where MUNE may be its most suitable derivate.
  35. [35]
    Update on recent advances in amyotrophic lateral sclerosis
    May 27, 2024 · ... CMAP amplitude from phrenic nerve stimulation predicts functional decline in ALS. ... predicting motor capacity in amyotrophic lateral sclerosis.
  36. [36]
    EMG and Nerve Conduction Studies in Clinical Practice
    Mar 9, 2010 · The use of nerve conduction studies (NCS) started with the work of Galvani who performed studies on frogs and observed twitching of the ...
  37. [37]
    Correlations of nerve conduction measures in axonal and ...
    Amplitude reductions are mainly due to axonal loss or presence of smaller calibre axons, but may be also influenced by demyelination when this leads to temporal ...
  38. [38]
    Peripheral Neuropathy – Clinical and Electrophysiological ...
    Lesions causing axon loss generally result in reduced CMAP and SNAP amplitudes. ... Any drop in CMAP amplitude or area of more than 20% implies conduction block ...
  39. [39]
    Action Potential Amplitude - an overview | ScienceDirect Topics
    In both side-to-side and interstimulus nerve locations for the same limb, an amplitude difference exceeding 50% may be considered pathologic.
  40. [40]
    NERVE CONDUCTION VELOCITY IN CMT1A: WHAT ELSE ... - NIH
    NCV was markedly and uniformly reduced. CMAP amplitudes were overall reduced but more severely in lower limbs. DML decreased and MNCV and SNCV increased with ...
  41. [41]
    Electrodiagnostic Findings in Neuromuscular Disorders - Thoracic Key
    Aug 12, 2016 · In conduction block, stimulation distal to the lesion elicits a normal CMAP, whereas proximal stimulation elicits a response with reduced ...
  42. [42]
    [PDF] European Federation of Neurological Societies/Peripheral Nerve
    At least 12 sets of electrodiagnostic criteria for primary demyelination have been published to identify CIDP (for review, see [1]). The EFNS/PNS criteria [3], ...Missing: prolonged | Show results with:prolonged
  43. [43]
    European Academy of Neurology/Peripheral Nerve Society ...
    Jul 30, 2021 · Motor nerve conduction criteria. (1) Strongly supportive of demyelination: At least one of the following: (a) Motor distal latency prolongation ...
  44. [44]
    Multifocal Motor Neuropathy - StatPearls - NCBI Bookshelf - NIH
    There may be evidence of demyelination marked by prolonged motor nerve latencies and slow conduction velocities. F-wave responses may be absent or prolonged.